Abstracts tagged "Classification criteria and systemic sclerosis"

Abstract Number: 2993 • 2015 ACR/ARHP Annual Meeting
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation
Serena Vettori¹, Rosaria Irace², Veronica Giacco², Antonella Riccardi², Lucia Vicedomini², Luciana Pellecchia² and Gabriele Valentini², ¹Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine, that has been shown to be increased in the sera of patients with systemic sclerosis (SSc)…
Abstract Number: 2714 • 2014 ACR/ARHP Annual Meeting
Application of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis in Korean Patients with Raynaud Phenomenon
Jin Su Park¹, Hee-Jin Park¹, You Jung Ha², Yong-Beom Park³, Soo-Kon Lee¹ and Sang-Won Lee⁴, ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁴Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea
Background/Purpose : The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) suggested the 2013 ACR/EULAR classification criteria for systemic sclerosis (SSc),…
Abstract Number: 757 • 2014 ACR/ARHP Annual Meeting
Distinctive Patterns of Telomere Shortening and Apoptosis in Limited and Diffuse cutaneous Systemic Sclerosis
Jasper Broen¹, Liane McGlynn², Dagmara McGuinness², Rina Wichers³, Jacqueline Thomson², Rajan Madhok⁴, Robert Lafyatis⁵, Carol A. Feghali-Bostwick⁶, Paul Shiels² and T.R.D.J. Radstake¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University of Glasgow, Glasgow, United Kingdom, ³UMC Utrecht, Utrecht, Netherlands, ⁴Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁵Arthritis Center, Boston University, Boston, MA, ⁶Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Aberrant telomere shortening and DNA damage-responses have been previously described in SSc, here we aim to validate these observations and incorporate them in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].